For research use only. Not for therapeutic Use.
Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell[1][2][3].
Mivacurium induces LAD2 cell degranulation in a dose-dependent manner. Mivacurium stimulates intracellular Ca2+ influx in MRGPRX2-HEK293 cells but not in NC-HEK293 cells. Mivacurium induces the release of only low levels of mediators in LAD2 cells transfected with MRGPRX2-targeted small interfering siRNA[1].
Mivacurium causes pseudo-allergic reactions in C57 wild-type mice by inducing mast cells to release histamine and a decrease in body temperature[1].
Mivacurium is rapidly hydrolyzed in the plasma and has a short duration of action (< 10 min). Mivacurium has many advantages, such as a rapid effect, nonneurological toxicity and a lack of heart rate alteration[1].
| Catalog Number | R008458 |
| CAS Number | 106861-44-3 |
| Synonyms | bis[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (E)-oct-4-enedioate;dichloride |
| Molecular Formula | C58H80Cl2N2O14 |
| Purity | ≥95% |
| InChI | InChI=1S/C58H80N2O14.2ClH/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10;;/h13-14,31-38,45-46H,15-30H2,1-12H3;2*1H/q+2;;/p-2/b14-13+;;/t45-,46-,59?,60?;;/m1../s1 |
| InChIKey | WMSYWJSZGVOIJW-ONUALHDOSA-L |
| SMILES | C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CCC=CCCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C.[Cl-].[Cl-] |
| Reference | [1]. Delu Che, et al. Mivacurium Induce Mast Cell Activation and Pseudo-Allergic Reactions via MAS-related G Protein Coupled receptor-X2. Cell Immunol. 2018 Oct;332:121-128. [2]. Matthias Paul, et al. The Potency of New Muscle Relaxants on Recombinant Muscle-Type Acetylcholine Receptors. Anesth Analg. 2002 Mar;94(3):597-603; table of contents. [3]. J E Caldwell. New Skeletal Muscle Relaxants. Int Anesthesiol Clin. Winter 1995;33(1):39-60. |
